Systematic Review and Meta-Analysis of Secondary Treatment Failure and Immunogenicity With Botulinum Neurotoxin A in Multiple Indications.

Eur J Neurol · 2025 · PMC12306683 · PMID 40729416

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

approached significancep = 0.08so close (0.05 < p ≤ 0.1)

The proportion of NAb‐positive patients with abobotulinumtoxinA was significantly higher versus incobotulinumtoxinA ( p = 0.009) and approached significance for onabotulinumtoxinA versus incobotulinumtoxinA ( p = 0.08, Figure 3B ); the difference between onabotulinumtoxinA versus incobotulinumtoxinA reached significance when all antibody testing was considered (Figure 3A ).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.